SlideShare a Scribd company logo
1 of 23
Joris Veltman (onderzoeker)
Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
Het probleem; Ineffectieve medicijnen!
1953
Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59  TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1  TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ?        OF   	Fout in aantal chromosomen?
Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
Genoomdiagnostiek in 2015  DNA ? Genoomsequentie < 1 uur < 500 euro
Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en  Bioinformatica expertise! Totale genoomsequentie 1 individu
ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
NRC 13 feb 2010
Personal genomics en impact op geneeskunde
Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen  verschillen
Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
THANK YOU !
NEXT

More Related Content

What's hot

Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
spa718
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
Analiese Wenger
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 Zincfinger
Ryla Best
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assays
nanog
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
Simon Silvan
 

What's hot (19)

Qpcr
QpcrQpcr
Qpcr
 
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
 
Present and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesPresent and future of oncolytic virus therapies
Present and future of oncolytic virus therapies
 
7 immunology-csbrp
7 immunology-csbrp7 immunology-csbrp
7 immunology-csbrp
 
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
 
PNAS 1992 FBH.PDF
PNAS 1992 FBH.PDFPNAS 1992 FBH.PDF
PNAS 1992 FBH.PDF
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
 
2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides
 
Seminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling systemSeminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling system
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 Zincfinger
 
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assays
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
 
HPV vaccine (UID198612)
HPV vaccine (UID198612)HPV vaccine (UID198612)
HPV vaccine (UID198612)
 
ProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene OlingerProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene Olinger
 
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsSources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
 
NK Immunodeficiencies
NK ImmunodeficienciesNK Immunodeficiencies
NK Immunodeficiencies
 

Similar to 03 joris veltman

2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
Simon Gemble
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013
Elsa von Licy
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013
Elsa von Licy
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
European School of Oncology
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Thermo Fisher Scientific
 

Similar to 03 joris veltman (20)

04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel
 
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
 
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
 
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013
 
Paneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosPaneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidos
 
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
 
Apoptosis
ApoptosisApoptosis
Apoptosis
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013
 
Diaz-Arrastia, Ramon
Diaz-Arrastia, RamonDiaz-Arrastia, Ramon
Diaz-Arrastia, Ramon
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
 
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
 
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDTuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MD
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptx
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
 
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
 

More from Radboud universitair medisch centrum

More from Radboud universitair medisch centrum (20)

UMC St Radboud: Jubileumsymposium kinderoncologie 'Kracht van schakels'
UMC St Radboud: Jubileumsymposium kinderoncologie 'Kracht van schakels' UMC St Radboud: Jubileumsymposium kinderoncologie 'Kracht van schakels'
UMC St Radboud: Jubileumsymposium kinderoncologie 'Kracht van schakels'
 
Umc st radboud cardiologie-hartfalenpoli-baltussen-mei-2013
Umc st radboud cardiologie-hartfalenpoli-baltussen-mei-2013Umc st radboud cardiologie-hartfalenpoli-baltussen-mei-2013
Umc st radboud cardiologie-hartfalenpoli-baltussen-mei-2013
 
Umc st radboud cardiologie-presentatie-bos-28-05-2013
Umc st radboud cardiologie-presentatie-bos-28-05-2013Umc st radboud cardiologie-presentatie-bos-28-05-2013
Umc st radboud cardiologie-presentatie-bos-28-05-2013
 
ZZG zorggroep
ZZG zorggroepZZG zorggroep
ZZG zorggroep
 
Zorg en Welzijns Info Portaal (ZWIP)
Zorg en Welzijns Info Portaal (ZWIP)Zorg en Welzijns Info Portaal (ZWIP)
Zorg en Welzijns Info Portaal (ZWIP)
 
Sociale wijkteams
Sociale wijkteamsSociale wijkteams
Sociale wijkteams
 
Up to date in erfelijke kanker (2013)
Up to date in erfelijke kanker (2013)Up to date in erfelijke kanker (2013)
Up to date in erfelijke kanker (2013)
 
Leukocorie
LeukocorieLeukocorie
Leukocorie
 
Corticosteroïden en Bacteriële cornea ulcera
Corticosteroïden en Bacteriële cornea ulceraCorticosteroïden en Bacteriële cornea ulcera
Corticosteroïden en Bacteriële cornea ulcera
 
Uveitis bij rifabutin gebruik
Uveitis bij rifabutin gebruik Uveitis bij rifabutin gebruik
Uveitis bij rifabutin gebruik
 
Glasvocht halfleeg of halfvol
Glasvocht halfleeg of halfvolGlasvocht halfleeg of halfvol
Glasvocht halfleeg of halfvol
 
OOG/ZOG: Intermediaire uveïtis 1 12-2012.pdf
OOG/ZOG: Intermediaire uveïtis 1 12-2012.pdfOOG/ZOG: Intermediaire uveïtis 1 12-2012.pdf
OOG/ZOG: Intermediaire uveïtis 1 12-2012.pdf
 
Voorlichting klinische fase
Voorlichting klinische faseVoorlichting klinische fase
Voorlichting klinische fase
 
OOG/ZOG: Van huet foveal sparing in patienten met m. stargardt
OOG/ZOG: Van huet   foveal sparing in patienten met m. stargardtOOG/ZOG: Van huet   foveal sparing in patienten met m. stargardt
OOG/ZOG: Van huet foveal sparing in patienten met m. stargardt
 
OOG/ZOG: Theelen, eengewonekeratitis
OOG/ZOG: Theelen, eengewonekeratitisOOG/ZOG: Theelen, eengewonekeratitis
OOG/ZOG: Theelen, eengewonekeratitis
 
OOG/ZOG: Phan oog zog 2012
OOG/ZOG: Phan oog zog 2012OOG/ZOG: Phan oog zog 2012
OOG/ZOG: Phan oog zog 2012
 
OOG/ZOG: Nobacht oogzog12
OOG/ZOG: Nobacht oogzog12OOG/ZOG: Nobacht oogzog12
OOG/ZOG: Nobacht oogzog12
 
OOG/ZOG: Keunen valmonte 2012
OOG/ZOG: Keunen valmonte 2012OOG/ZOG: Keunen valmonte 2012
OOG/ZOG: Keunen valmonte 2012
 
OOG/ZOG: Keijser zog oog
OOG/ZOG: Keijser zog oogOOG/ZOG: Keijser zog oog
OOG/ZOG: Keijser zog oog
 
Eggink oog zog 2012 creatief met cornea samenvatting eggink
Eggink oog zog 2012 creatief met cornea samenvatting egginkEggink oog zog 2012 creatief met cornea samenvatting eggink
Eggink oog zog 2012 creatief met cornea samenvatting eggink
 

Recently uploaded

Recently uploaded (20)

DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
hypo and hyper thyroidism final lecture.pptx
hypo and hyper thyroidism  final lecture.pptxhypo and hyper thyroidism  final lecture.pptx
hypo and hyper thyroidism final lecture.pptx
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 
HyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdfHyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdf
 
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdf
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaDR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in India
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 

03 joris veltman

  • 2. Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
  • 5. Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
  • 6.
  • 7. NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59 TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1 TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
  • 8. Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ? OF Fout in aantal chromosomen?
  • 9. Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
  • 10. Genoomdiagnostiek in 2015 DNA ? Genoomsequentie < 1 uur < 500 euro
  • 11. Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
  • 12. Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en Bioinformatica expertise! Totale genoomsequentie 1 individu
  • 13. ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
  • 14. NRC 13 feb 2010
  • 15. Personal genomics en impact op geneeskunde
  • 16. Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen verschillen
  • 17.
  • 18. Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
  • 19.
  • 20. Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
  • 21. Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
  • 23. NEXT